Yohimbine and Alpha-Yohimbine (Rauwolscine)

Yohimbine and alpha-yohimbine at a glance

Yohimbine is an alkaloid from yohimbe bark, and alpha-yohimbine, sold as rauwolscine, is its stereoisomer. Both block alpha-2 adrenergic receptors, a brake on fat release, which is why fat burners and stim formulas use them. In small trials, yohimbine lowered body fat percentage in professional footballers and raised sprint power in active women; alpha-yohimbine has no human trials for these uses. Yohimbine hydrochloride is a medicine in five EU countries, and in the UK products with yohimbine would normally be prescription-only medicines.

Evidence: Human trials (yohimbine), Animal studies (alpha-yohimbine) · Updated 19 November 2026

What yohimbine and alpha-yohimbine are

Yohimbine comes from the bark of Pausinystalia yohimbe, an evergreen tree. Supplements use it as yohimbine hydrochloride (yohimbine HCl), the salt also used in medicines.

Alpha-yohimbine, or rauwolscine, has the same chemical formula as yohimbine (C21H26N2O3) with its atoms arranged differently in space. Yohimbe bark contains both, plus a third related alkaloid, corynanthine. Hammer Labz Alpha Yohimbine uses an extract of Rauwolfia vomitoria root standardised to at least 90% alpha-yohimbine.

Content can vary between products: in an analysis of 18 yohimbe supplements, most did not contain the yohimbine amount stated on the label.

How they work

Fat cells carry two kinds of adrenaline receptors: beta receptors switch fat release on, and alpha-2 receptors hold it back. In human fat tissue, alpha-2 activation keeps fat in store by slowing its release and narrowing the small blood vessels that carry it away. There, yohimbine blocked this effect completely.

Yohimbine also raises noradrenaline. In healthy men, oral yohimbine raised blood glycerol and free fatty acids, markers of fat leaving fat cells, and lifted plasma noradrenaline by 40 to 50%.

Alpha-yohimbine works at the same receptors. In hamster fat cells, which share the human mix of beta and alpha-2 receptors, it lifted the alpha-2 brake on fat release about as strongly as yohimbine. Laboratories use labelled rauwolscine to measure binding at all three human alpha-2 receptor subtypes.

Evidence

Our evidence labels describe the ingredient, not a product; see how we review.

Yohimbine: Human trials. In a placebo-controlled trial, 20 professional male footballers took yohimbine or placebo for 21 days alongside resistance training. Body fat fell from 9.3% to 7.1% with yohimbine, while body mass, muscle mass and performance measures did not change.

In 20 women with obesity on a 1,000 kcal diet, three weeks of yohimbine brought 3.55 kg of weight loss, against 2.21 kg on placebo. Markers of fat release did not change significantly. In a crossover trial in 18 physically active women, a single dose of yohimbine HCl raised mean power and total work across three 15-second cycle sprints. Fatigue index and blood lactate were lower. All three trials are small and short.

Alpha-yohimbine: Animal studies. We found no human trial of alpha-yohimbine for fat loss, body composition or exercise performance (PubMed search, 19 November 2026). In people, we found it used as a laboratory tool, in a skin study of sweating during cycling.

Side effects. At high doses, the most frequent effects of yohimbine in clinical studies are higher blood pressure, mild anxiety and more frequent urination. Uptake varies widely between people, and large amounts have caused serious side effects. Check with a doctor first if you have high blood pressure, a heart condition or anxiety, or take any medication.

Amounts on labels

Hammer Labz productYohimbine HClAlpha-yohimbineLabel serving
Yohimbine HCL10 mg–1 capsule
Fury Caps5 mg4 mg2 capsules
Fireball Elite5 mg–10 g
Monster Strength (375 g Black Series)5 mg–1 scoop (15 g)
Diuretic Max2.5 mg–2 capsules
Oxy-Dren2 mg2 mgas listed on the panel
Alpha Yohimbine–2.5 mg of extract, min. 90% alpha-yohimbine1 capsule
Lipo Shred–2 mg2 capsules
Daily Pump–1.5 mg1 scoop (10 g)

Across these nine labels, yohimbine HCl appears at 2 to 10 mg and alpha-yohimbine at 1.5 to 4 mg.

Legal and anti-doping status

Status checked on 19 November 2026.

  • EU, food: the EU prohibits yohimbe bark and its preparations in foods. The EU novel food catalogue lists Rauwolfia vomitoria, the source of the alpha-yohimbine in Alpha Yohimbine, as not yet authorised.
  • EU, medicines: yohimbine hydrochloride is the active substance of medicines authorised in Austria, Belgium, France, Germany and Luxembourg. Rauwolscine does not appear in the European Medicines Agency’s database of authorised medicines.
  • UK: the MHRA has said that products containing yohimbine would normally be controlled as prescription-only medicines.
  • WADA: neither compound is named on the 2026 or 2027 WADA List. If you are a tested athlete, ask your anti-doping organisation before using either compound.
  • Not for drug-tested athletes: Fury Caps, Lipo Shred and Monster Strength 375 g list DMHA; Oxy-Dren lists DMAA; Fireball Elite lists ephedra, a plant source of ephedrine; Everbuild Nuke lists octopamine. WADA names DMAA, ephedrine, octopamine and octodrine, one of two compounds sold as DMHA, on its List. Each Hammer Labz product’s status is on our Hammer Labz page.

Status differs by country and changes over time.

Found in

Hammer Labz (brand page)

  • Yohimbine HCL
  • Alpha Yohimbine
  • Fury Caps (our Fury Caps review)
  • Diuretic Max
  • Oxy-Dren
  • Lipo Shred
  • Daily Pump
  • Fireball Elite
  • Monster Strength (375 g Black Series)

Haya Labs

  • Haya Yohimbine HCL 2.5 mg
  • Haya Yohimbine HCL 5 mg

Everbuild Nutrition

  • Nuke

We have not seen the Haya Labs labels, so we give no amounts. For Nuke, we confirmed yohimbine in the supplement facts its maker publishes.

Sources

  1. Product labels: Hammer Labz supplement facts panels for Yohimbine HCL, Alpha Yohimbine, Fury Caps, Diuretic Max, Oxy-Dren, Lipo Shred, Daily Pump, Fireball Elite and Monster Strength 375 g Black Series, as listed in November 2026.
  2. Galitzky J, Taouis M, Berlan M, et al. (1988). Alpha 2-antagonist compounds and lipid mobilization: evidence for a lipid mobilizing effect of oral yohimbine in healthy male volunteers. Eur J Clin Invest, 18(6), 587–594. PMID: 2906290.
  3. Galitzky J, Lafontan M, Nordenström J, et al. (1993). Role of vascular alpha-2 adrenoceptors in regulating lipid mobilization from human adipose tissue. J Clin Invest, 91(5), 1997–2003. PMID: 8387538.
  4. Tan S, Curtis-Prior PB (1984). Comparative effects of RX 781094, mianserin, yohimbine, rauwolscine and prazosin in reversing clonidine inhibition of MIX-stimulated lipolysis in hamster isolated white fat cells. Pharmacol Res Commun, 16(5), 461–466. PMID: 6204345.
  5. Proudman RGW, Akinaga J, Baker JG (2022). The affinity and selectivity of α-adrenoceptor antagonists, antidepressants and antipsychotics for the human α2A, α2B, and α2C-adrenoceptors and comparison with human α1 and β-adrenoceptors. Pharmacol Res Perspect, 10(2), e00936. PMID: 35224877.
  6. Porrill SL, Rogers RR, Ballmann CG (2024). Ergogenic and Sympathomimetic Effects of Yohimbine: A Review. Neurol Int, 16(6), 1837–1848. PMID: 39728757.
  7. Ostojic SM (2006). Yohimbine: the effects on body composition and exercise performance in soccer players. Res Sports Med, 14(4), 289–299. PMID: 17214405.
  8. Kucio C, Jonderko K, Piskorska D (1991). Does yohimbine act as a slimming drug? Isr J Med Sci, 27(10), 550–556. PMID: 1955308.
  9. Barnes ME, Cowan CR, Boag LE, et al. (2022). Effects of Acute Yohimbine Hydrochloride Supplementation on Repeated Supramaximal Sprint Performance. Int J Environ Res Public Health, 19(3), 1316. PMID: 35162339.
  10. Meng L, Wang H, Otsuka J, et al. (2025). Do Transdermal Administration of α1- and α2-Adrenergic Receptor Antagonists Modulate Sweating in Exercising Young Females in the Heat? Skin Pharmacol Physiol, 38(4), 149–158. PMID: 40532681.
  11. Tam SW, Worcel M, Wyllie M (2001). Yohimbine: a clinical review. Pharmacol Ther, 91(3), 215–243. PMID: 11744068.
  12. Sun J, Chen P (2012). Chromatographic fingerprint analysis of yohimbe bark and related dietary supplements using UHPLC/UV/MS. J Pharm Biomed Anal, 61, 142–149. PMID: 22221902.
  13. Cohen PA, Wang YH, Maller G, et al. (2016). Pharmaceutical quantities of yohimbine found in dietary supplements in the USA. Drug Test Anal, 8(3–4), 357–369. PMID: 26391406.
  14. National Library of Medicine. PubChem: Rauwolscine (CID 643606) and Yohimbine (CID 8969). Accessed 19 November 2026.
  15. European Union. Regulation (EC) No 1925/2006, Annex III: substances whose use in foods is prohibited, restricted or under scrutiny. Consolidated text of 15 May 2019, legislation.gov.uk. Accessed 19 November 2026.
  16. European Commission. EU Novel Food status catalogue: Rauwolfia vomitoria. Accessed 19 November 2026.
  17. European Medicines Agency. Article 57 product data: medicines authorised in the EU and EEA. Data file updated 12 November 2026. Accessed 19 November 2026.
  18. Medicines and Healthcare products Regulatory Agency (2021). Freedom of Information request on how many times have yohimbe/yohimbine, synephrine and ephedrine been reported to the Yellow Card Scheme since 2011 (FOI 21/779). Response of 5 August 2021, published 27 April 2022. Accessed 19 November 2026.
  19. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. In force from 1 January 2026. Accessed 16 November 2026.
  20. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2027. In force from 1 January 2027. Accessed 16 November 2026.
  21. Everbuild Nutrition. NUKE – Pre-workout. Product page and supplement facts image. Accessed 20 November 2026.